SHANGHAI FOSUN PHARMACEUTICAL Aktie

 

FOSUN PHARMA (02196.HK) announced that the drug registration application for the additional indication of Luvometinib Tablets has been approved by the National Medical Products Administration (NMPA). The approved indication is for the treatment of pediatric patients 2 years of age and older with relapsed or refractory Langerhans......

FOSUN PHARMA (02196.HK)'s controlling subsidiary Fosun Antengene plans to issue new shares to four investors, representing approximately 12.15% of the total enlarged share capital after the capital increase, raising RMB968 million (same below). Among them, external investors plan to subscribe for a total of RMB418 million, while......

FOSUN PHARMA (02196.HK) announced that its innovative oncology immunotherapy FXB0871 has completed dosing of the first participant in a Phase I clinical trial in China (excluding Hong Kong, Macau and Taiwan). FXB0871 is a PD-1-targeted attenuated IL-2 fusion protein immunotherapy (ATTENUKINE) jointly developed by FOSUN PHARMA an......

FOSUN PHARMA (02196.HK) announced that it officially signed a strategic cooperation framework agreement with GENRIX (688443.SH). The two parties will establish a long-term, stable and mutually trusting strategic partnership to accelerate the research and development and commercialization of innovative drugs, and jointly enhance ......

SHANGHAI and SEONGNAM, South Korea, May 13, 2026 /PRNewswire/ -- On 13 May, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma"; stock code: 600196.SH, 02196.HK) and AriBio Co., Ltd. ("AriBio"), a biopharmaceutical company focused on neurodegenerative diseases, today jointly......

CLSA issued a report stating that FOSUN PHARMA (02196.HK)'s results for 1Q26 slightly missed market expectations. Although revenue and profit recorded solid growth, mainly driven by the innovative drug segment, the healthcare services segment continued to face pressure. Nevertheless, management remains confident in achieving the......

SHANGHAI, April 28, 2026 /PRNewswire/ -- On 28 April, Fosun Pharma ("the Company", stock code: 600196.SH; 02196.HK) announced its results for the first quarter of 2026 (the reporting period). During the reporting period, the Company achieved a total revenue of RMB 10,073 million,......

FOSUN PHARMA (02196.HK) announced its first-quarter results, with revenue of RMB10.073 billion, up 6.9% YoY. Net profit attributable to shareholders amounted to RMB871 million, representing a 13.9% YoY increase. EPS was RMB0.33. (de/d)~AASTOCKS Financial NewsWebsite: www.aastocks.comThis article was automatically translated by A......

Strategic framework established for regional and global licensing, frontier technology incubation, and strategic collaboration in neurodegenerative diseases Joint R&D aligned with China-UAE bilateral partnership and Abu Dhabi's Healthcare Life Sciences Vision 2030 SHANGHAI, April 28, 2026......

Morgan Stanley said in a research report that it raised Fosun Pharma (02196.HK)'s revenue forecasts for 2026 to 2028 by 3%, driven by higher sales of innovative drugs and expected recurring licensing income of approximately RMB800 million per year.Meanwhile, it lowered net profit forecasts by 1%, 1% and raised by 4%, respectivel......

FOSUN PHARMA (02196.HK) announced that its subsidiary HENLIUS (02696.HK) has received approval from the National Medical Products Administration to conduct a Phase I clinical trial of HLX05-N (recombinant anti-EGFR human-mouse chimeric monoclonal antibody injection) for the treatment of metastatic colorectal cancer. HENLIUS plan......

Fosun Pharma (02196.HK) announced that its subsidiary Fosun Kairui has received approval from the National Medical Products Administration to conduct Phase I/II clinical trials of FKC289 injection for relapsed/refractory primary light-chain amyloidosis and relapsed/refractory membranous nephropathy. Fosun Kairui plans to carry o......

Fosun Pharma (02196.HK) announced that the board of directors has received a written resignation letter from Chen Zhanyu. Due to adjustments in work arrangements, Chen Zhanyu has applied to resign as Chief Financial Officer, effective April 2. Following the resignation, Chen Zhanyu will continue to serve as Senior Vice President......

Fosun Pharma (02196.HK) announced that its subsidiary, Shanghai Henlius Biotech and its holding subsidiary Henlius, have received approval from the National Medical Products Administration for HLX319 (pertuzumab-trastuzumab injection (subcutaneous) biosimilar) to conduct a Phase I clinical trial for neoadjuvant therapy in HER2-p......

Fosun Pharma (02696.HK) announced that the National Medical Products Administration (NMPA) has approved the Phase 1 clinical trial application (INDs) for its independently developed biosimilar injection HLX319 (subcutaneous injection) of pertuzumab-trastuzumab. The company plans to conduct related clinical trials in China once c......

Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...

Fosun Pharma (02696.HK) announced that the Phase 1 clinical trial application (IND) for its independently developed HLXTEHAase02 (recombinant human hyaluronidase injection) has been approved by the National Medical Products Administration (NMPA). The company plans to conduct the related clinical trials within mainland China (exc......

Fosun Pharma (02696.HK) announced that its independently developed Slulitinib Injection (HANSIZHUANG, HETRONIFLY) has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP). The recommendation is to approve HANSIZHUANG in combination with fluoropyrimidine and platin......

Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...

Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...